Pancreatic Cancer Global Pancreatic Cancer Market reached US$ 2.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 5.7 billion by 2030. The global Pancreatic Cancer market is expected to exhibit a CAGR of 11.1% during the forecast period (2024-2031).
Chemotherapy medications are used to kill or stop cancer cell division. Adjuvant chemotherapy is administered after surgery to eradicate any cancer cells left over, neoadjuvant chemotherapy is administered prior to surgery to reduce the tumor, and primary treatment for advanced or metastatic pancreatic cancer.
Market Dynamics
Increasing Prevalence of Pancreatic Cancer is Driving the Global Pancreatic Cancer Market Growth
Pancreatic cancer cases are increasing. Prior to implementing policies and interventions, it is critical to comprehend patterns in pancreatic cancer. Pancreatic cancer has a higher incidence, prevalence, and death in nations with high human development indices (HDI). The fourth greatest cause of cancer fatalities is pancreatic cancer, which is the tenth most prevalent cancer in men and the eighth most common in women.
The incidence of pancreatic cancer has increased as a result of obesity, passive smoking, and chronic inflammation. The risk of pancreatic cancer is influenced by what we eat and drink by 30% to 50%. As life expectancy rises along with a rising HDI, pancreatic cancer incidence is increasing in the Asia-Pacific region. Pancreatic cancer is underreported in underdeveloped nations in the Asia-Pacific area due to poor cancer registries.
FDA Approval for Products is Driving the Global Pancreatic Cancer Market Growth
For instance, in January 2022, the United States Food and Drug Administration (FDA) granted Orphan Drug designation to MT-601, a multi-tumor-associated antigen (MultiTAA)-specific T cell product optimized for the treatment of hematological malignancies and solid tumor indications produced by Marker Therapeutics, Inc., a clinical-stage immuno-oncology company.
Side Effects Associated with Therapeutics are Hampering the Global Pancreatic Cancer Market Growth
Therapeutics for pancreatic cancer can have a variety of side effects, which might differ depending on the exact treatment method and unique patient variables. Chemotherapy can cause vomiting and nauseous, feeble and weary, loss of hair decrease in appetite, constipation or diarrhea, mouth ulcers greater chance of infection, blood conditions (such as anemia and a low platelet count), perivascular neuropathy, which causes tingling or numbness in the hands or feet, depending on the chemotherapy medicines used, kidney or liver issues.
Market Segment Analysis
The global pancreatic cancer market is segmented based on type, end-user, and region.
Chemotherapy Segment is Expected to Hold A Dominant Position in the Market Over the Forecast Period
The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the pancreatic cancer market in 2022. Chemotherapy is typically most successful when two or more medications are administered concurrently (particularly as adjuvant or neoadjuvant therapy). A single medication (often gemcitabine, 5-FU, or capecitabine) may be administered for patients who are not healthy enough for combination therapies.
Gemcitabine, 5-fluorouracil (5-FU), Oxaliplatin, Albumin-bound Paclitaxel (Abraxane), Capecitabine (an oral 5-FU medicine), Cisplatin, and Irinotecan are the most popular medications used for both adjuvant and neoadjuvant chemotherapy.
Market Geographical Share
North Americba Holds a Dominant Position in the Global Pancreatic Cancer Market
North America is estimated to hold around 39.3% of the total market share throughout the forecast period. Rising pancreatic cancer and advancements in treatment and diagnosis boost regional growth over the forecast period. Estimates for pancreatic cancer in the United States for 2023 from the American Cancer Society state that a total of 64,050 individuals will receive a pancreatic cancer diagnosis (33,130 males and 30,920 women).
In total, 50,550 people will succumb to pancreatic cancer (26,620 males and 23,930 women). About 3% of cancer cases and 7% of cancer-related fatalities in the US are caused by pancreatic cancer.
Pancreatic Cancer Market Companies
The major global players in the market include Myriad Genetics Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Viatris Inc., Boston Scientific Corporation, Clovis Oncology, and GlaxoSmithKline among others.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war affected the pancreatic cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. People, including patients and medical personnel, displaced as a result of the violence. Displacement interfere with continuity of care, making it difficult for patients with pancreatic cancer to get timely and effective treatment.
Additionally, the delivery of care is impacted by the need for healthcare personnel to leave the area or by their having to work in challenging circumstances.
Artificial Intelligence Analysis
Artificial intelligence (AI) is increasingly being used in the pancreatic cancer market to improve various aspects of the customer experience. The goal of ongoing research and development is to find new treatment targets, investigate combination medicines, and advance early detection and diagnosis techniques. The market is anticipated to grow as a result of investments made in pancreatic cancer research and development initiatives.
By Treatment Type
• Targeted Therapies
• Chemotherapy
• Surgery
• Other Treatments
By End-user
• Hospitals
• Specialty Clinics
• Home care
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In October 2022, Erasca, based extended its current collaboration with Pfizer to evaluate ERAS-007 when combined with Pfizer's Ibrance (palbociclib). Both biopharma will start clinical proof-of-concept research as part of the extended clinical trial collaboration and supply agreement. They will test their drug combination on patients with colorectal cancer who have mutations in the NRAS and KRAS genes as well as pancreatic ductal adenocarcinoma who have mutations in the KRAS gene.
Why Purchase the Report?
• To visualize the global pancreatic cancer market segmentation based on the type, therapy type, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pancreatic cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global pancreatic cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet By Treatment Type
- 3.2. Snippet by End-user
- 3.3. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising prevalence of pancreatic cancer
- 4.1.2. Restraints
- 4.1.2.1. Side effects associated with therapeutics
- 4.1.3. Opportunity
- 4.1.3.1. Technological advancements
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers’ Strategic Initiatives
- 6.6. Conclusion
- 7. Russia-Ukraine War Analysis
- 8. Artificial Intelligence Analysis
- 9. By Treatment Type
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.1.2. Market Attractiveness Index, By Treatment Type
- 9.1.3. Targeted Therapies*
- 9.1.4. Introduction
- 9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.1.6. Chemotherapy
- 9.1.7. Surgery
- 9.1.8. Other Treatments
- 10. By End-user
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.1.2. Market Attractiveness Index, By End-user
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Home care
- 10.5. Others
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.5.1. U.S.
- 11.2.5.2. Canada
- 11.2.5.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.5.1. Germany
- 11.3.5.2. U.K.
- 11.3.5.3. France
- 11.3.5.4. Italy
- 11.3.5.5. Spain
- 11.3.5.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.5.1. Brazil
- 11.4.5.2. Argentina
- 11.4.5.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.5.1. China
- 11.5.5.2. India
- 11.5.5.3. Japan
- 11.5.5.4. Australia
- 11.5.5.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Product Benchmarking
- 12.3. Company Share Analysis
- 12.4. Key Developments and Strategies
- 13. Company Profiles
- 13.1. Myriad Genetics Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Pfizer Inc.
- 13.3. Novartis AG
- 13.4. Bristol-Myers Squibb Company
- 13.5. AstraZeneca PLC
- 13.6. Amgen Inc.
- 13.7. Viatris Inc.
- 13.8. Boston Scientific Corporation
- 13.9. Clovis Oncology
- 13.10. GlaxoSmithKline (*LIST NOT EXHAUSTIVE)
- 14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook